New tool aims to help seniors with advanced breast cancer make better treatment decisions
NCT ID NCT07599618
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new tool to help older adults (65+) with metastatic breast cancer and their care partners make treatment decisions together. Researchers want to see if the tool is acceptable, appropriate, and practical for use. The study involves 150 participants and focuses on gathering feedback, not on changing treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patient Inclusion Criteria: 1. A diagnosis of metastatic breast cancer 2. Age 65 or older 3. Currently receiving systemic treatment for metastatic breast cancer or considering a plan to initiate systemic treatment for metastatic breast cancer 4. Able to speak and read English (because the Manta Cares platform is presently only offered in English only) 5. Able to provide informed consent Care Partner Inclusion Criteria: 1. Age 18 or older 2. Able to speak and read English (because the Manta Cares platform is presently only offered in English only) 3. Able to provide informed consent 4. Verbal permission from patient to enroll their designated care partner Exclusion Criteria: Patient Exclusion Criteria: 1. Early-stage breast cancer 2. Diagnosis of any other cancer besides metastatic breast cancer Care Partner Exclusion Criteria: 1\. Verbal permission from patient to enroll care partner not received.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Rochester
Rochester, New York, 14620, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood test reveal when breast cancer treatment stops working?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Zapping a few growing tumors may keep breast cancer drugs working longer
- Can a Two-Drug combo outsmart resistant breast and ovarian cancers?
- Can a platform trial match the right drug combo to each tumor?
- Can a vaccine teach the immune system to fight HER2-Positive tumors?